Study to Assess Safety and Clinical Responses With Coartem® Baby Dispersible Tablets in Paediatric Patients Weighing 2 to <5 kg With Uncomplicated Malaria

Starting soon · Phase 4

Conditions studied: Malaria

In brief

This study is being conducted to further evaluate the safety and clinical outcomes of Coartem® Baby (artemether/lumefantrine 5 mg/60 mg) in neonates and infants weighing ≥2 kg to \<5 kg with uncomplicated malaria due to Plasmodium falciparum or mixed infections under real-world conditions.

Key facts

Study ID

NCT07713602

Run by

Novartis Pharmaceuticals

People needed

20

Starts

2027-06-18

Expected to finish

2028-05-31

Last updated by the study team

2026-07-20

Who can join

Age: any, up to 1. Sex: any. Healthy volunteers: not accepted.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.